CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier F-34094, France.
Drug Resist Updat. 2010 Feb-Apr;13(1-2):44-56. doi: 10.1016/j.drup.2009.01.002. Epub 2010 Feb 21.
During the last 25 years, improvements in our understanding of signaling processes mediating tumor initiation, growth and dissemination have opened the door towards increasingly efficient, selective, but also complex therapeutic approaches. In parallel, the better characterization of altered signaling pathways in tumor cells, as well as the relationship between these alterations and the sensitivity of tumors to given compounds, have forced us to contemplate the use of biomarkers allowing patient selection and evaluation of treatment efficacy. Such biomarkers should become a corner stone for the success of a more rational and "personalized" clinical approach to colorectal cancer. Here we give an overview of the "signaling pathway-selective" compounds that are currently in use or under clinical development in the setting of colorectal cancer (CRC) and we discuss promising targets, based on our current knowledge of colorectal tumor cell biology, such as Src family, Wnt and Hegdehog signaling.
在过去的 25 年中，我们对介导肿瘤发生、生长和扩散的信号转导过程的理解不断提高，为越来越有效、选择性但也越来越复杂的治疗方法开辟了道路。与此同时，肿瘤细胞中改变的信号通路的更好表征，以及这些改变与肿瘤对特定化合物的敏感性之间的关系，迫使我们考虑使用生物标志物来进行患者选择和治疗效果评估。此类生物标志物应该成为更合理和“个体化”的结直肠癌临床治疗方法取得成功的基石。在这里，我们概述了目前在结直肠癌 (CRC) 治疗中使用或处于临床开发阶段的“信号通路选择性”化合物，并根据我们对结直肠肿瘤细胞生物学的现有知识，讨论了有前途的靶点，如Src 家族、Wnt 和 Hedgehog 信号。
